【作者】 冯铭恩；

【导师】 冯亮；

【作者基本信息】 南昌大学 ， 外科学， 2010， 硕士

【摘要】 目的:研究信号传导和转录激活因子3(signal transducers and activators of transcription3,STAT3)和CD147在前列腺癌组织中的表达水平以及探讨其与肿瘤分化程度、Gleason评分、PSA值之间的关系。方法:60例前列腺癌组织,按不同分化程度、PSA值和Gleason评分高低分类,良性前列腺增生(benign prostatic hyperplasia,BHP)15例,应用免疫组化方法检测各组织中STAT3、CD147的表达水平。了解STAT3、CD147在前列腺增生、前列腺癌组织中表达的差异,以及找出STAT3、CD147与前列腺癌的不同分化程度、PSA值和Gleason评分高低的关系。免疫组化染色原理:利用抗原抗体间的特异性免疫反应,通过标记抗体与组织细胞中的抗原发生免疫反应,再用适当的显色方法对标记抗体上的标记物进行显色反应,通过显微镜对显色物的观察确定待检测抗原的组织细胞学位置和抗原的数量。结果:1、STAT3阳性表达的细胞浆或细胞核呈现呈棕黄色或棕褐色颗粒,CD147的阳性表达的细胞浆呈现呈棕黄色或棕褐色颗粒,良性前列腺增生组的阳性率为STAT3 40.0%、CD147 26.6%,PCa中STAT3、CD147阳性表达率分别为73.3%、61.7%,PCa中STAT3、CD147阳性表达率高于BPH,(P均<0.05)。前列腺癌的胞浆着色深。2、高Gleason评分组中STAT3、CD147阳性表达率高于低Gleason评分组。3、所有前列腺癌中的STAT3、CD147阴性表达集中在高分化肿瘤组,低分化组中的强阳性率STAT3为41.6℅, CD147为37.5%;PSA<4的前列腺癌的阴性率STAT3为70.0℅, CD147为80.0%; PSA>20的前列腺癌则全部表达阳性,强阳性率STAT3为57.1℅, CD147也为57.1%,随着肿瘤的分化程度的降低和PSA值的增加,STAT3、CD147阳性率相应增高。4、STAT3、CD147在前列腺癌中表达的相关性做Spearman等级相关分析,rs′=0.7757,P<0.01,二者正相关。结论:1、STAT3、CD147在前列腺癌组织中的表达明显强于良性前列腺增生组织。2、高Gleason评分组中STAT3、CD147阳性表达率高于低Gleason评分组。低分化组前列腺癌的STAT3、CD147阳性表达率明显高于高分化组。3、STAT3、CD147在前列腺癌中的表达随着PSA值的升高而增强, STAT3、CD147与前列腺癌的发生、发展、转移等生物学行为有密切关系。更多还原

【Abstract】 Objectives:To investigate the expression of signal transducers and activators of transcription 3 (STAT3)and CD147 in human prostate cancer(PCa)to explore their relationship with cell differentiation ,PSA and Gleason Scoring.Methods:To understand the differences of STAT3、CD147 expressions among Benign Prostatic Hyperplasia and Prostate Cancer and to seek out the relationships between the various pathological ratings of prostate cancer and STAT3、CD147 as well as the relationships between PSA and Gleason Scoring, researchers stained 15 cases of Benign Prostatic Hyperplasia specimens and 60 cases of prostate cancer specimens .The expression of STAT3 ande CD147 were dectected by means of immunohistochemistry. The principle of immunohistochemical staining: There are some differential immunolo- gical reactions between marked antibodies and antigens in histiocytes. Then, tumor markers on marked antibodies react to developers. Last, we can definite detected antigens’quantity and cytological location by observing chromogenic objects with microscope.Results:1. The positive expressions of STAT3 and CD147 in prostatic tissues are stained from yellow to brown in cytoplasm. Only one positive expressions of STAT3 and only one positive expressions of CD147 in normal prostate and the color is lighter yellow, the positive rate of STAT3 and CD147 in Benign Prostatic Hyperplasia is 40.0℅ and 26.6%,but the positive rate reach to 73.3℅ and 61.7% in prostate cancer , whose color in cytoplasm is deeper. The positive rates of STAT3 and CD147 in PCa was higher than those in BPH ( P<0.05).2. The positive rates of STAT3 and CD147 in Gleason scoring group were higher than those in low Gleason scoring group.3.All of the negative STAT3 and CD147 expressions are distributed in well differential tumors ,the highly positive rate of STAT3 and CD147in poorly differential tumors are 41.6℅ and 37.5℅;70.0% and 80.0% negative expression in the group of PS cell differentiation A<4; 100℅ positive expression in the group of PSA>20, moreover,57.1℅and 57.1%highly positive expression in the group of PSA> 20.The postive rate of STAT3 and CD147 corresponds with the increase of tumor’s pathological grading and its PSA and furthermore with deeper color in cytoplasm.4.And using Spearman rank correlation analysis ,There was a positive correlation between the expression of STAT3 and that of CD147(rs′=0.7757,P<0.01).Conclusion:1.The expression of STAT3 and CD147 in prostate cancer is higher than that in Benign Prostatic Hyperplasia.2. The positive rates of STAT3 and CD147 in high Gleason score group were higher than those in low Gleason score group. The positive rates of STAT3 and CD147 in poorly differential tumors were higher than those in well differential tumors.3. The expression of STAT3 and CD147 in prostate cancer present positive correlation with PSA. The expression presents close relation with the carcinogenesis, progression and metastasis of prostate cancer.更多还原